WO2000057719A1 - Additifs pour aliments de crustacees ou de poissons et aliments - Google Patents
Additifs pour aliments de crustacees ou de poissons et aliments Download PDFInfo
- Publication number
- WO2000057719A1 WO2000057719A1 PCT/JP2000/001764 JP0001764W WO0057719A1 WO 2000057719 A1 WO2000057719 A1 WO 2000057719A1 JP 0001764 W JP0001764 W JP 0001764W WO 0057719 A1 WO0057719 A1 WO 0057719A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fish
- crustaceans
- disease
- low
- molecular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Definitions
- the present invention relates to a crustacean or fish feed additive and a feed to which the feed additive is added, and in particular, a feed additive having a remarkable effect on immunostimulation and infectious disease prevention, and an appropriate ratio of this feed additive.
- the present invention relates to feedstuffs added in, and preventive and breeding methods using them.
- antibiotics and synthetic antibacterials are used as remedies for bacterial diseases, but resistant bacteria against the antibacterial substances have appeared, and sufficient therapeutic effects have not been obtained.
- public health problems have arisen due to the use of the drug in shellfish and fish, preventive measures that do not rely on chemotherapy are strongly desired.
- vaccines and remedies have not been developed for crustacean and fish virus diseases, and the disease is still occurring frequently.
- peptide darican derived from Bifidobacterium thermophilum (Patent No. 2547371), cell walls of Gram-positive bacteria such as Bacillus sp. Ingredients (Tokuhei 3—1 7 3 8 2 6 It is already known to use polysaccharides such as i3-1-1,3-glucan derived from Suehirotake (Japanese Patent Publication No. 6-65649). Also, it has been reported that high molecular weight lipopolysaccharide activates the immune function of fish (Sal at i, F. and R.
- the low-molecular-weight lipopolysaccharide (hereinafter, abbreviated as low-molecular-weight LPS) used in the present invention is basically composed of the above-mentioned peptide darican derived from a gram-positive bacterium, a cell wall component, and 3-1 and 3-glucan derived from a mushroom. It has a different structure and components, and is composed of a specific lipid lipid A, an oligosaccharide called R-core covalently bonded to the lipid A, and a ⁇ specific polysaccharide. It is a substance composed of three components, and is based on the enhancement of tumor necrosis factor (TNF) production effect for animals.
- TNF tumor necrosis factor
- crustaceans and fish are prone to various infectious diseases, some of which can result in death, causing enormous economic damage. This is due to the reduced immune function of these crustaceans or fish due to overcrowding in restricted environments.
- Various substances have already been used to activate reduced immune functions, but crustaceans do not have the ability to produce antibodies, and lymphocytes, neutrophils, and neutrophils found in vertebrates do not.
- the ability to produce antibodies is limited in fish, such as the absence of base spheres.Furthermore, antibody production is greatly affected by water temperature because it is a variable temperature animal. Both have significant differences in the defense mechanisms of mammals, such as the inadequate function of such immune functions (Fish Pathology, 30 (2), 141-150, 1995.6). Satisfactory for prevention of crustacean and fish infectious diseases due to the fact that it may not be used in aquaculture sites due to its high toxicity, such as LPS, and its immune function is rather reduced after long-term administration. There was nothing I could do.
- An object of the present invention is to activate the immune function inherently provided by crustaceans and fish in a very small amount to prevent infectious diseases, and to provide a safe crust free from public health problems such as drug residues.
- An object of the present invention is to provide a feed additive for growing fishes and fish, a feed to which the feed additive is added, and a preventive method and a breeding method using the same. Disclosure of the invention
- the present invention relates to a low-molecular-weight lipopolysaccharide obtained from gram-negative microbial cells and having a molecular weight of 5000 ⁇ 2000 as measured by SDS-PAGE using a protein marker and substantially containing no high-molecular-weight lipopolysaccharide.
- the present invention relates to a feed additive for crustaceans or fishes having an immunostimulatory effect and a preventive effect against infectious diseases, characterized by containing a ride as an active ingredient.
- the present invention also relates to a feed additive for crustaceans or fish containing the low-molecular-weight lipopolysaccharide and a carrier acceptable to crustaceans and fish.
- the present invention also relates to the use of the low-molecular-weight lipopolysaccharide for producing a crustacean or fish feed additive.
- the present invention also relates to a method for immunostimulating crustaceans or fish and preventing infectious diseases, which comprises administering an effective amount of the low-molecular-weight lipopolysaccharide to crustaceans or fish.
- the present invention also relates to a crustacean or fish mortality preventive agent comprising the low-molecular-weight lipopolysaccharide as an active ingredient.
- the present invention also relates to the low molecular weight lipopolysaccharide and a pharmaceutically acceptable carrier.
- the present invention relates to a crustacean or fish mortality preventive agent containing a body.
- the present invention also relates to the use of the low molecular weight lipopolysaccharide for producing a crustacean or fish mortality preventive agent.
- the present invention also relates to a method for preventing death of crustaceans or fish, comprising feeding an effective amount of the low-molecular-weight lipopolysaccharide to crustaceans or fish.
- the present invention also relates to a feed additive for crustaceans or fishes, wherein the gram-negative microorganism cells are microorganism cells belonging to the genus Pantoea.
- the present invention also relates to a feed additive for crustaceans or fish wherein the gram-negative microbial cell is Pantoea agglomerans.
- the present invention also relates to a crustacean or fish feed to which the above-mentioned feed additive or mortality preventive agent has been added.
- the present invention also relates to a method for breeding crustaceans or fish, wherein the feed is fed to crustaceans or fish.
- the present invention relates to a substance purified from gram-negative microbial cells by, for example, the method disclosed in Japanese Patent Application Laid-Open No. 8-189902, and has a low molecular weight LPS of 500,000 ⁇ 200,000.
- LPS low molecular weight
- the low-molecular-weight LPS of the present invention has a molecular weight of 500,000 obtained from gram-negative microbial cells, for example, by the method disclosed in Japanese Patent Application Laid-Open No. 8-189902.
- Ability to describe lipopolysaccharide of 0 ⁇ 20000 The feature is that its safety against crustaceans and fish is higher than conventional high molecular weight LPS (molecular weight 1,000,000 to 100,000), and is remarkable. It has an excellent immune activating effect, an infectious disease preventive effect, and a mortality preventive effect.
- substantially not containing a high molecular weight lipopolysaccharide means not containing a lipopolysaccharide having a molecular weight of 800 or more.
- examples of the gram-negative microbial cells include microorganisms belonging to the genus Pantoea, Salmonella, Aeromonas, Serratia, Enterobaclos, etc. Gram-negative microbial cells can be mentioned. Preferred microorganisms are those belonging to the genus Pantoea, more preferably Pantoea agglomerans.
- the low-molecular-weight LPS of the present invention is obtained by culturing a gram-negative microorganism or the like by a conventional method, collecting cells from a culture medium, and then using a known method from the collected cells, for example, a hot phenol method [ ⁇ -Westfar ( ⁇ ) Westphal), Ed., Methods in Carbohydrate Chemistry, Volume 5, Page 83, Academic Press, 1966.5], and more. It can be produced by purification using an anion exchange resin. That is, microbial cells are suspended in distilled water, this suspension is added to a mixture of distilled water and an equal volume of hot phenol, and the mixture is stirred, and then centrifuged to collect an aqueous layer.
- the layer is dialyzed to remove the phenol, concentrated by ultrafiltration to collect the crude LPS fraction, and this fraction is subjected to conventional anion exchange chromatography (e.g., Mono Q-Sepharose or Is purified using Q-Sepharose) and desalted by a conventional method.
- conventional anion exchange chromatography e.g., Mono Q-Sepharose or Is purified using Q-Sepharose
- the purified LPS thus obtained is disclosed in JP-A-4-1187640, JP-A-4-49240, JP-A-4-99948 and JP-A-5-155778. It is substantially equivalent to the disclosed molecular weight of about 5,000 to 6,000 LPS. Further, the obtained purified LPS is subjected to gel filtration in the presence of a surfactant such as sodium deoxycholate to recover only a fraction containing low-molecular-weight LPS and remove mixed high-molecular-weight LPS. As a result, highly purified low molecular weight LPS of the present invention can be obtained.
- a surfactant such as sodium deoxycholate
- the crustaceans that are the subject of the present invention include all lobsters including lobsters, such as prawns (Penaeus japonicus), prawns (Penaeus monodon), prawns (Penaeus chinensis), and prawns (Penaeus morguiensis).
- lobsters such as prawns (Penaeus japonicus), prawns (Penaeus monodon), prawns (Penaeus chinensis), and prawns (Penaeus morguiensis).
- shrimp, prawn) Shanghai crab, thistle, etc., preferably shrimp, and more preferably kuruma shrimp.
- Fish includes all fish, such as puri, puffer fish, red sea bream, flounder, eel and rainbow trout.
- Infectious diseases include acute crustacean viremia, vibrio disease, parasitic diseases such as Bpisty
- Zoothamnium sp. Mycosis such as Lagenidium sp. And Siropidium sp., Irid virus infection in fish, Rhabdovirus disease, Neuronecrosis, Infectious hematopoietic necrosis, Nodulation disease, Streptococcal disease, Enterococci disease, Vibrio disease, Cold water disease, Pseudomonas disease, Gliding bacterium disease, Hydrobic disease, and all viruses, Infections caused by mycoplasmas, bacteria, fungi and parasites, preferably acute crustacean viremia, streptococcal fish in fish, enterococcal disease, vibriopathy.
- Irid virus infection in fish Rhabdovirus disease, Neuronecrosis, Infectious hematopoietic necrosis, Nodulation disease, Streptococcal disease, Enterococci disease, Vibrio disease, Cold water disease, Pseudomonas disease, Gliding bacterium disease
- low molecular weight LPS may be used as it is or by adding known carriers, stabilizers, etc., and further, if necessary, various nutrients such as vitamins, amino acids, and minerals, antioxidants, antibiotics, and antibacterial agents.
- additives may be added to make a feed additive for crustaceans or fish, and the shape may be adjusted to an appropriate state such as powder, granules, pellets, suspensions, etc. .
- crustaceans or fish may be fed alone, or may be fed as a mixture with feed. Feeding may be done at all times to prevent disease, or added at the latter half of feeding.
- the feed of the present invention is not particularly limited, and may be powder feed, solid feed, Any feed can be used, including pellet pellet feed, dry pellet feed, EP (Extruder Pellet) feed, and raw feed.
- the amount of the low molecular weight LPS to be added to the feed additive or the feed can be selected from a wide range, but is preferably 0.00000001 to 0.001% by weight, particularly preferably the feed additive or the feed.
- the power is 0.00000 to 0.00005% by weight.
- the amount of low-molecular-weight LPS to be fed may be determined as appropriate.For example, daily doses of 1 to 100 g, preferably 10 to 20 g per kg of crustaceans and fish, should be administered.
- the low molecular weight LPS used in the examples is an LPS having a molecular weight of about 50,000
- the high molecular weight LPS is an LPS having a molecular weight of 8,000 to 50,000.
- L-one broth medium 100 ml
- a single colony was isolated and inoculated from a strain of Pantoea agglomerans stored at -80 in a 500-ml 1-volume Sakaguchi flask and shake-cultured overnight at 35.
- a 3 liter Sakaguchi flask containing 1, 000 ml of L broth medium was inoculated and cultured in the same manner.
- the obtained crude LPS lyophilized product is dissolved in distilled water, filter-sterilized, buffer is added, and subjected to anion exchange chromatography (Pharmacia, Q-Sepharose Fast Flow), and 1 OmM Tris_HC1
- the sample solution was passed through the column with a buffer containing (pH 7.5) and 1 OmM NaCl, and the limulus-active fraction was eluted with 200 to 400 mM NaClZl OmM Tris-HCl (H7.5).
- the eluate was subjected to ultrafiltration under the same conditions as above, desalted and concentrated, and lyophilized to obtain about 30 Omg of purified LPS from about 70 g of wet cells.
- the obtained purified LPSIOOmg was dissolved at a concentration of 5 mgZml in a solubilization buffer [3% sodium hydroxycholate (manufactured by Wako Pure Chemical Industries) 0.2 M sodium chloride, 5 mM EDTA—2Na and 2 OmM Tris—HCl
- a solubilization buffer [3% sodium hydroxycholate (manufactured by Wako Pure Chemical Industries) 0.2 M sodium chloride, 5 mM EDTA—2Na and 2 OmM Tris—HCl
- the purified LPS solution was gently layered on top of a Sephacryl S-200 HR column (Pharmacia), and the elution buffer [0.25% sodium doxycholate] was dissolved in pH8.3.
- each fraction was mixed, lyophilized, suspended in ethanol, centrifuged to remove ethanol-soluble dexocholic acid, and low-molecular-weight LPS was recovered as an insoluble fraction.
- the ethanol treatment of the low molecular weight LPS fraction was repeated twice more to remove dexcholate, then resuspended in 70% ethanol, centrifuged to remove the buffer components, and repeated this operation three more times.
- the low molecular weight LPS was recovered in the insoluble fraction, lyophilized, and purified to obtain about 2 Omg of low molecular weight LPS.
- the shrimp with an average body weight of 20 g were divided into 5 groups of 20 fish each, and the low molecular weight LPS (molecular weight of about 5,000) of the present invention was weighed 1 kg or 1 Og for the shrimp and 5 Omg for the 2nd shrimp.
- Omg and conventional high molecular weight LPS LPS derived from E. coli, E. coli 0111, manufactured by DI FC ⁇ , molecular weight of about 8,000 to 50,000
- 10 mg in section 3 and 4 in section 4 was administered intramuscularly in the third gastrocnemius so as to be 2 Omg.
- District 5 includes LP S No saline was administered. The survival of the shrimp up to 120 hours after the administration was confirmed, and the mortality was determined. The results are shown in Table 1.
- the mortality in the 1 Omg and 2 Omg sections of the high molecular weight LPS was 65 and 100%, respectively, whereas the mortality rates in the low molecular weight LPS section were 5 Omg and 10 Omg. Did not show any dead individuals. From this, it is clear that the low-molecular-weight LPS of the present invention is a substance having extremely high safety against shrimp as compared with the conventional high-molecular-weight LPS.
- Magoi with an average body weight of 85 g was divided into three groups of 40 fishes per group, and 1 kg of low molecular weight LPS 10 Omg / kg and 2 high molecular weight LPS (E. coli 0 1 1 1) , Manufactured by DI FCO) was administered intramuscularly in each case. In the 3rd section, physiological saline without LPS was administered. The survival of Magoi up to 120 hours after the administration was confirmed, and the mortality was determined. The results are shown in Table 2.
- the prawns with an average body weight of 20 g were divided into 6 groups of 20 fish, and in the sections 1, 2 and 3 of the present invention, the low molecular weight LPS was set to be 20. 400 and 100 ig, and high molecular weight LPS were mixed with the feed so as to obtain 100 g in the fourth section and 100 ⁇ g in the fifth section, and were administered for 7 days. Section 6 was fed LPS-free feed. On days 0, 1, 5, and 7 after administration, blood was collected from the shrimp thoracic sinus using a syringe containing K-199 medium containing L-cysteine as an anticoagulant, and blood cells were obtained by centrifugation. Was.
- Phagocytosis rate [number of blood cells incorporating beads Z total number of observed blood cells] X 1 0 0
- the phagocytic index of blood cells in the shrimp to which low-molecular-weight LPS was administered was higher in all of the inventive groups than in the 6 groups, and a significant difference was observed (0 ⁇ 0.01). , 0.05).
- the phagocytosis index of blood cells in conventional shrimp to which 100 g of high molecular weight LPS was administered did not increase at 1, 5, and 7 days after administration. Also significantly increased (P 0.05). From the above, it is clear that the low-molecular-weight LPS of the present invention is much smaller than the high-molecular-weight LPS and activates the biological defense ability such as the phagocytic activity of shrimp blood cells.
- the prawns with an average body weight of 20 g were divided into 6 groups of 20 fish, and low-molecular-weight LPS was used as a daily dose per 1 kg of shrimp weights in sections 1, 2, and 3 of the plots of the present invention.
- 40, 100 / zg, and high molecular weight LPS were mixed with feed at 100 ⁇ g in section 4 and 100 xg in section 5 and administered for 7 days.
- Section 6 was fed LPS-free feed.
- blood was collected from the thoracic sinus of the shrimp using a syringe containing KHE medium containing EDTA, and blood cells were obtained by centrifugation.
- Test results The host defense mechanism of crustaceans is composed of cellular factors and humoral factors, and the latter is deeply involved in the PO activity of blood cells. The presence or absence is also revealed by examining PO activity. Therefore, the P ⁇ activity of the low-molecular-weight LPS section and the high-molecular-weight LPS section of the present invention at 0, 1, 5, and 7 days after the start of administration was examined.
- the ⁇ activity of blood cells in the shrimp to which the low-molecular-weight LPS was administered was higher in all the inventive groups than in the 6 groups, and a significant difference was observed ( ⁇ ⁇ 0.01). , 0.05).
- the PO activity of blood cells in the conventional shrimp administered with 100 g of high-molecular-weight LPS did not increase until 7 days after administration, and was significantly higher in the 1000 g group than in the 6 and 5 days after administration. (P ⁇ 0. 05). From the above, it is clear that the low-molecular-weight LPS of the present invention is much smaller than the high-molecular-weight LPS and activates biological defense functions such as PO activity of shrimp blood cells.
- the prawns with an average body weight of 14 g were divided into 5 groups of 20 fish, and in sections 1, 2 and 3 of the plot of the present invention, low molecular weight LPS was used as a daily dose per kg of shrimp weights of 20 and 40, respectively. , 100 ig, and in the fourth section, high-molecular-weight LPS was mixed with the feed so as to become 1,000 g and administered for 18 days.
- the amount of peptidoglycan (PG) derived from Bifidobacterium samorphophilum described in Japanese Patent No. 2547371 is 0.2 mgZkg (200 Mg / kg).
- PRDV penaeid rod-shaped DNA virus
- the infection was performed by removing the head and chest shells of the three shrimp killed by the disease, homogenizing in 40 ml of sterile seawater, and centrifuging (10,000 Xg, 10 minutes, 4 minutes). ) was added to 20 liters of seawater.
- LPS was infected by a method of immersing the shrimp 8 days after the start of administration for 2 hours. The death status was observed for 10 days after infection, and the dead shrimp was Inspection by the PCR (Polymerase chain reaction) method confirmed that death was due to PRDV.
- Test results Cumulative mortality and mortality of prawns after PRDV infection in the low-molecular-weight LPS section, high-molecular-weight LPS section and LPS-free section of the present invention are shown in Tables 5 and 6 [Table 5].
- the staff with an average body weight of 230 g was divided into 6 groups of 20 fish, and in the first, second and third sections of the present invention, low-molecular-weight LPS was used as a daily dose per kg of the male.
- g and high molecular weight LPS were mixed into moist pellets at 100 / X g in section 4 and 100 2 g in section 5, and administered for 7 days.
- Section 6 received moist pellets without LPS.
- the head kidney was excised from each of the five pre-purities, and blood cells were separated in a plastic dish containing 0.25% NaCl-added RPM1-1640-HAH medium Then, the mixture was passed through a cell strainer to obtain a cell suspension. This solution was layered on a discontinuous density gradient of percoll, and then centrifuged at 1,600 rpm for 20 minutes (at 4) to obtain a leukocyte layer.
- the means having an average body weight of 63 g was divided into 5 groups of 30 fish each.
- low-molecular-weight LPS was used as a daily dose per kg of shrimp weights of 20, 40, and 100, respectively.
- high molecular weight LPS was mixed with a moist pellet so as to be 1000 g, and administered daily.
- Five control plots received a moisture pellet without LPS.
- enterococcus seriolicida a causative agent of enterococci, was intraperitoneally inoculated at 4.0 x 10 6 cells per fish, and the mortality rate was determined for 15 days after inoculation. .
- Tables 9 and 10 The results are shown in Tables 9 and 10.
- the immune function of crustaceans and fish is precisely and precisely activated in a very small amount to prevent infectious diseases, to prevent crustaceans and fish from dying, and to improve public health such as drug residues. It is possible to provide feed additives and feed for raising safe crustaceans and fish without any problem.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00911297T ATE440502T1 (de) | 1999-03-26 | 2000-03-23 | Zusaetze fuer krustentier- bzw. fischfuttermittel sowie futtermittel |
CA002333160A CA2333160C (en) | 1999-03-26 | 2000-03-23 | Additives for crustacean or fish feeds and feeds |
DE60042807T DE60042807D1 (de) | 1999-03-26 | 2000-03-23 | Zusaetze fuer krustentier- bzw. fischfuttermittel sowie futtermittel |
EP00911297A EP1082908B1 (en) | 1999-03-26 | 2000-03-23 | Additives for crustacean or fish feeds and feeds |
AU33257/00A AU757122C (en) | 1999-03-26 | 2000-03-23 | Additives for crustacean or fish feeds and feeds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8439999 | 1999-03-26 | ||
JP11/84399 | 1999-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000057719A1 true WO2000057719A1 (fr) | 2000-10-05 |
Family
ID=13829510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/001764 WO2000057719A1 (fr) | 1999-03-26 | 2000-03-23 | Additifs pour aliments de crustacees ou de poissons et aliments |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1082908B1 (ja) |
KR (1) | KR20010071331A (ja) |
CN (1) | CN100473284C (ja) |
AT (1) | ATE440502T1 (ja) |
AU (1) | AU757122C (ja) |
CA (1) | CA2333160C (ja) |
DE (1) | DE60042807D1 (ja) |
ES (1) | ES2330300T3 (ja) |
TW (1) | TWI272914B (ja) |
WO (1) | WO2000057719A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075928B2 (en) | 2003-09-26 | 2011-12-13 | Gen-Ichiro Soma | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
JP2015023832A (ja) * | 2013-07-26 | 2015-02-05 | 克史 小早川 | 飲料水 |
JP2015027299A (ja) * | 2008-04-24 | 2015-02-12 | エウォス、イノベーション、アクティーゼルスカブEwos Innovation As | 機能性飼料組成物 |
US20220016240A1 (en) * | 2020-06-26 | 2022-01-20 | Zivo Bioscience, Inc. | Immune priming to accelerate/enhance immune response through administration of natural immune modulator |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100483911B1 (ko) * | 2001-05-14 | 2005-04-18 | 주식회사 메디오젠 | 양식어류의 면역증강과 항병력강화 및 증체를 위한 사료첨가제 |
WO2005084704A1 (en) * | 2004-03-02 | 2005-09-15 | Peros Systems Technologies Inc. | Digestive bypass composition for arthropod and uses thereof |
FI20085812A0 (fi) * | 2008-09-01 | 2008-09-01 | Esa-Matti Lilius | Karkea LPS immunostimulanttina vesiviljelyssä |
CN101461940B (zh) * | 2009-01-09 | 2011-01-26 | 中国水产科学研究所南海水产研究所 | 美人鱼发光杆菌疫苗及其制备方法和应用 |
KR101040186B1 (ko) * | 2009-10-12 | 2011-06-09 | 주식회사 진우씨스템 | 배선덕트 커버 |
KR101519506B1 (ko) * | 2012-06-07 | 2015-05-18 | 주식회사제이엔비바이오 | 새우사료 첨가제 조성물 및 그 제조방법 |
KR101854016B1 (ko) | 2015-11-13 | 2018-06-20 | 주식회사 네오엔비즈 | 바이오플락 유용유기물을 포함하는 사료첨가제와 그 생산방법 |
KR101857327B1 (ko) | 2015-11-16 | 2018-06-19 | 주식회사 네오엔비즈 | 바이오 플락 양식과정에서 생산되는 유용유기물을 원료로 포함하는 사료 및 사료제조방법 |
CN108552435A (zh) * | 2018-04-12 | 2018-09-21 | 福建高农饲料有限公司 | 高体鰤鱼人工配合饲料及其制备方法 |
CN116075317A (zh) * | 2020-06-26 | 2023-05-05 | 齐沃生物科学股份有限公司 | 通过施用天然免疫调节剂来加速/增强免疫反应的免疫引发 |
CN113647516A (zh) * | 2021-07-26 | 2021-11-16 | 中农科生物工程技术(苏州)有限公司 | 链壶菌诱抗蛋白质LiiP1的制备方法及应用 |
CN115029267B (zh) * | 2022-06-20 | 2022-12-27 | 聚芯生物工程有限公司 | 一种对虾用抗病促生长的复合型饲料添加剂及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472467A2 (en) * | 1990-08-20 | 1992-02-26 | Chiba Flour Milling Co. Ltd. | LPS-Containing analgesics and veterinary analgesics |
EP0592220A2 (en) * | 1992-10-07 | 1994-04-13 | Eisai Co., Ltd. | Pharmaceutical composition or feedstuff containing a plant substance |
JPH06141849A (ja) * | 1992-10-30 | 1994-05-24 | Genichiro Soma | Lps産生菌、lps、免疫機能活性化剤及び動物用免疫機能活性化剤 |
WO1996023002A1 (fr) * | 1995-01-27 | 1996-08-01 | Taiho Pharmaceutical Co., Ltd. | Lipopolysaccharide de faible poids moleculaire |
JPH08280332A (ja) * | 1995-04-18 | 1996-10-29 | Natl Fedelation Of Agricult Coop Assoc | 飼料用添加剤 |
JPH10279486A (ja) * | 1997-04-02 | 1998-10-20 | Taiyo Kagaku Co Ltd | 免疫賦活組成物 |
-
2000
- 2000-03-23 AT AT00911297T patent/ATE440502T1/de not_active IP Right Cessation
- 2000-03-23 DE DE60042807T patent/DE60042807D1/de not_active Expired - Fee Related
- 2000-03-23 CA CA002333160A patent/CA2333160C/en not_active Expired - Lifetime
- 2000-03-23 WO PCT/JP2000/001764 patent/WO2000057719A1/ja active IP Right Grant
- 2000-03-23 EP EP00911297A patent/EP1082908B1/en not_active Expired - Lifetime
- 2000-03-23 CN CNB00800398XA patent/CN100473284C/zh not_active Expired - Lifetime
- 2000-03-23 KR KR1020007013326A patent/KR20010071331A/ko active IP Right Grant
- 2000-03-23 ES ES00911297T patent/ES2330300T3/es not_active Expired - Lifetime
- 2000-03-23 AU AU33257/00A patent/AU757122C/en not_active Expired
- 2000-03-24 TW TW089105420A patent/TWI272914B/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472467A2 (en) * | 1990-08-20 | 1992-02-26 | Chiba Flour Milling Co. Ltd. | LPS-Containing analgesics and veterinary analgesics |
EP0592220A2 (en) * | 1992-10-07 | 1994-04-13 | Eisai Co., Ltd. | Pharmaceutical composition or feedstuff containing a plant substance |
JPH06141849A (ja) * | 1992-10-30 | 1994-05-24 | Genichiro Soma | Lps産生菌、lps、免疫機能活性化剤及び動物用免疫機能活性化剤 |
WO1996023002A1 (fr) * | 1995-01-27 | 1996-08-01 | Taiho Pharmaceutical Co., Ltd. | Lipopolysaccharide de faible poids moleculaire |
JPH08280332A (ja) * | 1995-04-18 | 1996-10-29 | Natl Fedelation Of Agricult Coop Assoc | 飼料用添加剤 |
JPH10279486A (ja) * | 1997-04-02 | 1998-10-20 | Taiyo Kagaku Co Ltd | 免疫賦活組成物 |
Non-Patent Citations (4)
Title |
---|
FULVIO SALATI ET AL.: "Effect of Edwardsiella tarda Lipopolysaccharide Immunization on Phagocytosis in the Eel", NIPPON SUISAN GAKKAISHI, vol. 53, no. 2, 1987, pages 201 - 204, XP002928719 * |
L.W. CLEM ET AL.: "MONOCYTES AS ACCESSORY CELLS IN FISH IMMUNE RESPONSES", DEVELOPMENT AND COMPARATIVE IMMUNOLOGY, vol. 9, 1985, pages 803 - 809, XP002928721 * |
MARILYN J. ODEAN ET AL.: "Involvement of Gamma Interferon in Antibody Enhancement by Adjuvants", INFECTION AND IMMUNITY, vol. 58, no. 2, 1990, pages 427 - 432, XP002928720 * |
YUKINORI TAKAHASHI, YOUSHOKU, vol. 34, no. 10, 1997, pages 117 - 121, XP002935493 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075928B2 (en) | 2003-09-26 | 2011-12-13 | Gen-Ichiro Soma | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
EP2444480A1 (en) | 2003-09-26 | 2012-04-25 | Gen-Ichiro Soma | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
US9394513B2 (en) | 2003-09-26 | 2016-07-19 | Gen-Ichiro Soma | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant |
JP2015027299A (ja) * | 2008-04-24 | 2015-02-12 | エウォス、イノベーション、アクティーゼルスカブEwos Innovation As | 機能性飼料組成物 |
JP2015023832A (ja) * | 2013-07-26 | 2015-02-05 | 克史 小早川 | 飲料水 |
US20220016240A1 (en) * | 2020-06-26 | 2022-01-20 | Zivo Bioscience, Inc. | Immune priming to accelerate/enhance immune response through administration of natural immune modulator |
Also Published As
Publication number | Publication date |
---|---|
AU757122B2 (en) | 2003-02-06 |
KR20010071331A (ko) | 2001-07-28 |
CA2333160C (en) | 2005-10-18 |
DE60042807D1 (de) | 2009-10-08 |
CN100473284C (zh) | 2009-04-01 |
KR100400352B1 (ja) | 2003-10-04 |
AU757122C (en) | 2004-11-25 |
EP1082908A4 (en) | 2004-10-13 |
ES2330300T3 (es) | 2009-12-09 |
CA2333160A1 (en) | 2000-10-05 |
ATE440502T1 (de) | 2009-09-15 |
EP1082908B1 (en) | 2009-08-26 |
EP1082908A1 (en) | 2001-03-14 |
CN1306399A (zh) | 2001-08-01 |
AU3325700A (en) | 2000-10-16 |
TWI272914B (en) | 2007-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohan et al. | Potential uses of fungal polysaccharides as immunostimulants in fish and shrimp aquaculture: a review | |
Peddie et al. | Immunostimulation in the rainbow trout (Oncorhynchus mykiss) following intraperitoneal administration of Ergosan | |
WO2000057719A1 (fr) | Additifs pour aliments de crustacees ou de poissons et aliments | |
Bøgwald et al. | The stimulatory effect of a muscle protein hydrolysate from Atlantic cod, Gadus morhuaL., on Atlantic salmon, Salmo salarL., head kidney leucocytes | |
CN111961617B (zh) | 一株高产免疫多糖和细菌素的多效枯草芽孢杆菌及应用 | |
JP2021120383A (ja) | 免疫機能を調節するため及び腸の炎症を治療するためのベータ−1,3−グルカンの使用 | |
Montero-Rocha et al. | Immunostimulation of white shrimp (Litopenaeus vannamei) following dietary administration of Ergosan | |
JP2012527416A (ja) | 食事介入による胃腸の健康、免疫および働きの改善 | |
Velmurugan et al. | Screening and characterization of antimicrobial secondary metabolites from Halomonas salifodinae MPM-TC and its in vivo antiviral influence on Indian white shrimp Fenneropenaeus indicus against WSSV challenge | |
US20170290853A1 (en) | Methods to facilitate the solubilization of beta-1,3-glucan and enhance immune function and other related uses | |
US5494819A (en) | Pure culture of Pantoea agglomerans ferm BP-3511 | |
AU642804B2 (en) | Preventive agent against infectious disease of crustacea | |
US20050175711A1 (en) | Shark cartilage extracts and use thereof for immunomodulation | |
JP2000103740A (ja) | 魚介類用薬剤及び飼料 | |
JP2747293B2 (ja) | 細菌感染に対する非特異的防御を刺激するための薬剤 | |
JP4448330B2 (ja) | マツタケ由来陰イオン交換樹脂吸着画分、免疫増強剤、及びストレス負荷回復促進剤 | |
US10889608B2 (en) | Ester of aminoglycan and uses thereof | |
US20110070269A1 (en) | Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof | |
CN115992116B (zh) | 一种多功能奶牛溶菌酶及其制备方法和应用 | |
JP4422404B2 (ja) | 感染予防・治療剤および食品 | |
WO2011038186A1 (en) | Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof | |
JPH06263649A (ja) | 免疫賦活剤 | |
JPH0690745A (ja) | Lps産生菌、lps、lpsを含む医薬及び動物薬 | |
EP0890648A1 (en) | Non-toxic lipopolysaccharide and its preparation | |
KR20240136479A (ko) | 상황버섯 균사체 유래 포스트바이오틱스 및 이를 포함하는 면역 활성 증강 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00800398.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000911297 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2333160 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 33257/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007013326 Country of ref document: KR Ref document number: 09700713 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2000911297 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007013326 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 33257/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007013326 Country of ref document: KR |